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T
he concept of whether there are mutual substitutions
of antibodies on cell surfaces has not received much
attention to date, presumably because it does not look
important. However, it could be far more relevant than
first appearance because most, if not all, allergic diseases
could be cured if nonpathogenic antibodies substituted
pathogenic antibodies on the surface of mast cells.
In 1976, Turton reported that his hay fever had been
cured after three time–repeated infections and extermina-
tions of hookworm.
1 In 1979, Kojima hypothesized in a
domestic journal that antihookworm antibodies might
have saturated all Fc receptors on Turton’s mast cells.
2
If there were only two antibody molecules on a cell, their
mutual substitution could occur in a probability of 1/2
because an equilibrium state exists between free and cell-
bound antibodies. If there were three antibody molecules,
the probability would be 2/3. It follows that when N
antibody molecules are present, the probability of their
mutual substitution is (N-1)/N. There are numerous
antibody molecules bound to mast cells. Therefore, the
probability, (N-1)/N, is virtually equal to 1. A logical
conclusion is that mutual substitutions of antibodies do
occur on cell surfaces without fail.
Supporting the above theory are the results of the
following case. In 1995, a 31-year-old woman with an egg
allergy was treated with injections with a nonspecific antigen
preparation, Asthremedin (Nippon Zohki Pharmaceutical
Company, Osaka, Japan). Her blood samples were taken
before and 4 months after the start of treatment. Ovalbumin
and Asthremedin were separately labeled with fluorescence.
Aliquots of her blood taken before the treatment were
separately incubated with labeled ovalbumin and labeled
Asthremedin in an ice bath for 20 minutes. Ratios of
leukocytes that became fluorescent during the incubation
were analyzed using flow cytometry. Before treatment, the
ratio of leukocytes that became fluorescent during the
incubation with the labeled ovalbumin was 16.2% (mean of
a duplicate test), whereas the ratio of leukocytes that became
fluorescent during the incubation with labeled Asthremedin
was 0.02% (mean of a duplicate test). After 4 months, the
respective ratios were 9.6% and 17.4%. These results
demonstrate that there were substitutions of antibody
molecules on the surface of leukocytes.
Repeated intradermal injections at 2- to 7-day intervals
with a nonspecific antigen preparation, for example, killed
microorganisms, may be a successful treatment of allergic
disease. The appropriate initial dose would depend on the
severity ofthe disease,that is,themoreseverethedisease,the
less the initial dose. The least initial dose in my experience
has been 1 ng protein of killed Neisseria sicca et flava (Itoyu
Pharmaceutical Company, Osaka, Japan). In most cases, 10
ng protein of killed Neisseria sicca et flava was used as the
initial dose. The dose was raised by 50% after every 10-time
repetition.Mixing one-fifth ofthe volumewith 1%lidocaine
solution softened the pain accompanying the intradermal
injection. The average necessary period of treatment has
been one-thirteenth of the duration of the disease.
The total number of cases I have seen during the last 15
years is 721, consisting of various allergies and atopic
conditions. There has been no case of failure except for
those who dropped out of the treatment. In addition, this
treatment has caused no disagreeable side effects. The
absence of failed cases implies that this treatment is reliable
and deserves further study.
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